

# Press Release

Regulated information

## ARSEUS DIVESTS DENTAL DISTRIBUTION, LAB AND SOFTWARE ACTIVITIES TO HENRY SCHEIN

Waregem (Belgium) / Rotterdam (the Netherlands)<sup>1</sup>, 6 January 2014 – Arseus announces today that it has successfully completed the sale of its Dentals software Julie, Arseus Dental Lab, Arseus Dental Solutions Benelux and Arseus Dental Solutions France Ouest to Henry Schein (NASDAQ: HSIC) for a total cash consideration of € 50 million. Henry Schein is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, headquartered in Melville, N.Y., United States. Together the divested activities represent annual sales of approximately € 70 million and these activities are deconsolidated as of 1 January 2014.

As announced in the press release of 2 August 2013 the Board of Directors of Arseus started an analysis of strategic options, both inside and outside Arseus, for the Healthcare Solutions and Healthcare Specialties divisions. This deal marks an important step in completion of this process.

The Board of Directors expects more news to be announced regarding the remaining activities in Healthcare Solutions and Healthcare Specialties in the first semester of 2014.

Ger van Jeveren, CEO of Arseus: *"We are convinced that the dental distribution, lab and software activities will contribute to the future growth and expansion of Henry Schein's European dental presence. This transaction enables Arseus to continue to invest in its global roll out of the Fagron activities, to further develop Corilus and to focus on the successful execution of its innovation strategy to create concepts and solutions with substantial added value."*

Furthermore, the transaction regarding the sale of the French dental distribution activities in the regions Paris, Lille and Lyon to MS Distribution, as announced on 7 November 2013, has been closed.

---

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

## **Other information**

Arseus was represented in this transaction by Nielen Schuman as financial advisor and by Allen & Overy LLP as legal counsel.

## **Conference call**

Ger van Jeveren (CEO) and Jan Peeters (CFO) will provide further details on this transaction during a conference call scheduled for Monday, 6 January. The conference call starts at 9:30 a.m. CET. You can join from 09:15 a.m. CET onwards by calling +31 10 713 72 95 (Netherlands) or +32 2 404 03 34 (Belgium).

From 10:30 a.m. CET onwards a recording of the conference call may be listened to by calling telephone number +31 20 713 34 87 and typing in access code 451014. From Tuesday, 7 January, the conference call may be listened to or downloaded from the corporate website of Arseus ([www.arseus.com](http://www.arseus.com)).

*In the event of any discrepancy between the Dutch translation and the original English version of this press release, the latter shall prevail.*

## **For more information, please contact:**

Marieke Palstra  
Director Investor Relations  
Tel. +31 88 33 11 213  
Mob. +31 6 10 31 64 64  
marieke.palstra@arseus.com

## **About Arseus**

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem (Belgium), and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam (the Netherlands).

## **About Henry Schein, Inc.**

Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs nearly 16,000 Team Schein Members and serves nearly 800,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items.

The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record \$8.9 billion in 2012, and have grown at a compound annual rate of 17% since Henry Schein became a public company in 1995. For more information, visit the Henry Schein web site at [www.henryschein.com](http://www.henryschein.com)